Infinite Intelligence Pharma (IIP) Co., Ltd. is an artificial intelligence-driven start-up company aiming to cutting-edge drug innovations. IIP’s research and development were originated from the accumulated research of Peking University Molecular Design Laboratory in the past 30 years. In 2015, the research team published the first AI drug design paper in China. Since then, the research team has been an AI drug design leader team in pharmaceutical industry specially in First-in-Class and Best-in-Class drug R&D. IIP has built an AI drug design platform, PharmaMindTM and an AI target evaluation platform “TopTargets”. PharmaMind is a leading AI new drug research and development platforms with state-of-the-art practical drug design methods. IIP has a globally leading success rate in AI drug design. Generally, by designing and testing 50-80 molecules, new structural candidate drug molecules can be designed from scratch, reflecting the practical implementation of IIP’s AIDD platform. IIP has also established the world’s first target discovery large language model system TargetGPT and the first small molecular drug generative large model system PharmGPT (TM). Currently, with PharmGPT (TM), we have reproduced 83% of FDA approved drug molecules; we have also obtained a candidate drug molecule for target PLK1 and a highly active lead compound for target PCAB, with only 4 and 7 designed and tested molecules, respectively.